Difference between revisions of "Drug index"
Jump to navigation
Jump to search
m (→F) |
m (→V) |
||
| Line 231: | Line 231: | ||
*[[Vinorelbine (Navelbine)]] | *[[Vinorelbine (Navelbine)]] | ||
*[[Vismodegib (Erivedge)]] '''FDA approved 1/30/2012''' | *[[Vismodegib (Erivedge)]] '''FDA approved 1/30/2012''' | ||
| − | *[[Von Willebrand Factor | + | *[[Von Willebrand Factor and factor VIII complex]] |
*[[Vorinostat (Zolinza)]] | *[[Vorinostat (Zolinza)]] | ||
Revision as of 05:59, 29 February 2012
- List of chemotherapy regimens
- Vesicant & irritant chemotherapy
- Antiemetic support
- Steroid conversions
A
- Abiraterone (Zytiga) FDA approved 4/28/2011
- Afatinib (BIBW 2992) in clinical trials
- Aflibercept (Zaltrap) in clinical trials
- Aldesleukin (Proleukin)
- Alemtuzumab (Campath)
- All-trans retinoic acid (ATRA)
- Altretamine (Hexalen)
- AMG 386 in clinical trials
- Amifostine (Ethyol)
- Aminoglutethimide (Cytadren)
- Amsacrine (Amsidine)
- Anagrelide (Agrylin)
- Anastrozole (Arimidex)
- Arsenic trioxide (Trisenox)
- Asparaginase (Elspar)
- Asparaginase Erwinia chrysanthemi (Erwinaze) FDA approved 11/18/2011
- Atovaquone (Mepron)
- Axitinib (Inlyta) FDA approved 1/27/2012
- Azacitidine (Vidaza)
B
- Bacillus Calmette-Guerin (BCG, TheraCys)
- Bendamustine (Treanda)
- Bevacizumab (Avastin)
- Bexarotene (Targretin)
- Bicalutamide (Casodex)
- BHQ880 (Anti-DKK1 Antibody) in clinical trials
- Bleomycin (Blenoxane)
- Bortezomib (Velcade)
- Brentuximab vedotin (Adcetris) FDA approved 8/19/2011
- Busulfan (Myleran)
- Bosutinib (SKI-606) in clinical trials
C
- Cabazitaxel (Jevtana)
- Cabozantinib (XL184) in clinical trials
- Capecitabine (Xeloda)
- Carboplatin (Paraplatin)
- Carmustine (BiCNU)
- Catumaxomab (Removab) in US clinical trials
- Cetuximab (Erbitux)
- Chlorambucil (Leukeran)
- Cisplatin (Platinol)
- Cladribine (Leustatin)
- Clofarabine (Clolar)
- Crizotinib (Xalkori)
- Cyclophosphamide (Cytoxan)
- Cytarabine (Cytosar)
- Cytarabine liposomal (DepoCyt)
- Cytomegalovirus (CMV) Human Immunoglobulin (Cytogam)
D
- Dabigatran (Pradaxa)
- Dacarbazine (DTIC)
- Dactinomycin (Cosmegen)
- Dasatinib (Sprycel)
- Daunorubicin (Cerubidine)
- Daunorubicin liposomal (DaunoXome)
- Decitabine (Dacogen)
- Deferasirox (Exjade)
- Deferiprone (Ferriprox) - FDA approved 10/14/2011
- Deferoxamine (Desferal)
- Degarelix (Firmagon)
- Denileukin diftitox (Ontak)
- Denosumab (Xgeva)
- Dexamethasone (Decadron)
- Dexrazoxane (Zinecard)
- Docetaxel (Taxotere)
- Doxorubicin (Adriamycin)
- Doxorubicin liposomal (Doxil)
- Dutasteride (Avodart)
E
- Eculizumab (Soliris)
- Elotuzumab (HuLuc63) in clinical trials
- Eltrombopag (Promacta)
- Epirubicin (Ellence)
- Eribulin (Halaven)
- Erlotinib (Tarceva)
- Estramustine (Emcyt)
- Etoposide (Vepesid)
- Everolimus (Afinitor)
- Exemestane (Aromasin)
F
- Factor VIIa, recombinant (NovoSeven RT)
- Factor VIII, human and recombinant (antihemophilic factor 8)
- Factor VIII and von Willebrand Factor
- Factor IX, human and recombinant (coagulation factor 9)
- Factor XIII concentrate, human (Corifact)
- Ferumoxytol (Feraheme)
- Filgrastim (Neupogen)
- Finasteride (Proscar)
- Fluorouracil (5-FU)
- Floxuridine (FUDR)
- Fludarabine (Fludara)
- Flutamide (Eulexin)
- Folinic acid (Leucovorin)
- Fulvestrant (Faslodex)
G
- Ganetespib (STA-9090) in clinical trials
- Ganitumab (AMG 479) in clinical trials
- Gefitinib (Iressa)
- Gemcitabine (Gemzar)
- Gemtuzumab ozogamicin (Mylotarg)
- Glucarpidase (Voraxaze) FDA approved 1/17/2012
- Goserelin (Zoladex)
H
- Hematopoetic progenitor cells, cord blood (Hemacord) - FDA approved 11/10/2011
- Hydroxyurea (Hydrea)
I
- Ibritumomab tiuxetan (Zevalin)
- Idarubicin (Idamycin)
- Ifosfamide (Ifex)
- Imatinib (Gleevec)
- Ipilimumab (Yervoy)
- Interferon alfa-2a (Roferon-A)
- Interferon alfa-2b (Intron-A)
- IPH 2101 (Anti-KIR) in clinical trials
- Irinotecan (Camptosar)
- Ixabepilone (Ixempra)
L
- Lapatinib (Tykerb)
- Lenalidomide (Revlimid)
- Letrozole (Femara)
- Leuprolide (Lupron)
- Levoleucovorin (Fusilev)
- Lomustine (Ceenu)
M
- Mechlorethamine (Mustargen)
- Melphalan (Alkeran)
- Mercaptopurine (Purinethol)
- Mesna (Mesnex)
- Methotrexate (MTX)
- Mitomycin (Mutamycin)
- Mitotane (Lysodren)
- Mitoxantrone (Novantrone)
N
- Nelarabine (Arranon)
- Neratinib (HKI-272) in clinical trials
- Nilotinib (Tasigna)
- Nilutamide (Nilandron)
O
- Obinutuzumab (GA101) in clinical trials
- Octreotide (Sandostatin)
- Ofatumumab (Arzzera)
- Olaparib (AZD-2281)
- Omacetaxine mepesuccinate (Omapro) in clinical trials
- Onartuzumab (MetMAb) in clinical trials
- Oxaliplatin (Eloxatin)
P
- Paclitaxel (Taxol)
- Paclitaxel, nanoparticle albumin-bound (Abraxane)
- Panitumumab (Vectibix)
- Pazopanib (Votrient)
- PCI-32765 in clinical trials
- Pegaspargase (Oncaspar)
- Pegfilgrastim (Neulasta)
- Peginterferon alfa-2a (Pegasys)
- Peginterferon alfa-2b (PegIntron)
- Pemetrexed (Alimta)
- Pentamidine (Nebupent)
- Pentostatin (Nipent)
- Pertuzumab (Omnitarg) in clinical trials
- Plerixafor (Mozobil)
- Plicamycin (Mithracin)
- Pomalidomide (Actimid) in clinical trials
- Ponatinib (AP24534) in clinical trials
- Porfimer (Photofrin)
- Pralatrexate (Folotyn)
- Prednisone (Sterapred)
- Procarbazine (Matulane)
R
- Raloxifene (Evista)
- Regorafenib (BAY 73-4506) in clinical trials
- Rituximab (Rituxan)
- Romidepsin (Istodax)
- Romiplostim (Nplate)
- Ruxolitinib (Jakafi) - FDA approved 11/16/2011
S
- Sargramostim (Leukine)
- Sipuleucel-T (Provenge)
- Sorafenib (Nexavar)
- Streptozocin (Zanosar)
- Sunitinib (Sutent)
T
- Tamoxifen (Nolvadex)
- Temozolomide (Temodar)
- Temsirolimus (Torisel)
- Teniposide (Vumon)
- Thalidomide (Thalomid)
- Thioguanine (Tabloid)
- Thiotepa (Thioplex)
- Topotecan (Hycamtin)
- Toremifene (Fareston)
- Tositumomab & I-131 (Bexxar)
- Trabectedin (Yondelis)
- Trastuzumab (Herceptin)
- Trastuzumab emtansine (T-DM1) in clinical trials
- Tretinoin (Vesanoid)
- Trimethoprim/Sulfamethoxazole (Bactrim DS)
- Triptorelin (Trelstar LA)
U
V
- Valrubicin (Valstar)
- Vandetanib (Caprelsa) FDA approved 4/6/2011
- Vemurafenib (Zelboraf) FDA approved 8/17/2011
- Vinblastine (Velban)
- Vincristine (Oncovin)
- Vincristine liposomal (Marqibo) in clinical trials
- Vindesine (Eldisine)
- Vinorelbine (Navelbine)
- Vismodegib (Erivedge) FDA approved 1/30/2012
- Von Willebrand Factor and factor VIII complex
- Vorinostat (Zolinza)
Z
Reference
- Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article - with chemotherapy sequencing chart